APA Alıntı

Zhang, Y., Ishida, C., Karpel-Massler, G., & Siegelin, M. (2018). CBMT-37. FDA-APPROVED HDAC INHIBITORS ANTAGONIZE THE WARBURG EFFECT AND CAUSE UNIQUE METABOLIC VULNERABILITIES. Neuro Oncol.

Chicago Stili Alıntı

Zhang, Yiru, Chiaki Ishida, Georg Karpel-Massler, ve Markus Siegelin. "CBMT-37. FDA-APPROVED HDAC INHIBITORS ANTAGONIZE THE WARBURG EFFECT AND CAUSE UNIQUE METABOLIC VULNERABILITIES." Neuro Oncol 2018.

MLA Alıntı

Zhang, Yiru, Chiaki Ishida, Georg Karpel-Massler, ve Markus Siegelin. "CBMT-37. FDA-APPROVED HDAC INHIBITORS ANTAGONIZE THE WARBURG EFFECT AND CAUSE UNIQUE METABOLIC VULNERABILITIES." Neuro Oncol 2018.